Specialty and country guide
Medical oncology uses anticancer medicines such as chemotherapy, immunotherapy, targeted therapy and hormone therapy. The appropriate regimen, dose, route and number of cycles depend on pathology, stage, biomarkers, previous treatment, organ function and the patient’s goals; a medical oncologist must review those factors before treatment or cost can be estimated.
Specialty overview
Medical oncology is the specialty responsible for assessing and delivering systemic anticancer treatment. Unlike surgery or radiation, a systemic medicine can circulate through the body, although route, tissue penetration and biological target differ by treatment. The medical oncologist interprets pathology, stage, molecular findings, prior response and the patient’s health to define treatment intent and choose an evidence-based regimen.
A treatment name is not a complete prescription. Chemotherapy requires named medicines, doses, cycle intervals and supportive care. Immunotherapy and targeted treatment require indication-specific evidence and may require a biomarker. Hormone therapy depends on receptor biology. Cellular therapy and transplantation involve eligibility assessment, collection or donor planning, conditioning, inpatient capability and prolonged monitoring.
Treatment may be curative, neoadjuvant before local treatment, adjuvant after surgery, maintenance after response, or palliative for disease control and symptoms. Benefit and toxicity are reassessed during treatment. A multidisciplinary team may include surgical and radiation oncologists, pathologists, radiologists, organ-specific specialists, pharmacists, nurses, nutrition teams and palliative-care clinicians.
Clinical scope
A specialty can have diagnostic, medical, procedural, supportive or palliative roles. A diagnosis alone does not establish that any listed therapy is appropriate.
Pathology, stage, hormone receptors, HER2 status, genomic context and previous treatment determine whether chemotherapy, endocrine, targeted, immune or antibody-drug conjugate therapy may be considered.
Related treatment guides: Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy
Histology, stage, performance status and molecular testing can distinguish chemotherapy, immunotherapy and alteration-directed treatment pathways.
Related treatment guides: Chemotherapy, Immunotherapy, Targeted Therapy, Precision Oncology
Site, stage, resectability, pathology and relevant biomarkers shape perioperative, advanced-disease and selected intraperitoneal treatment decisions.
Related treatment guides: Chemotherapy, Targeted Therapy, Immunotherapy, Neoadjuvant Chemotherapy
Systemic therapy may be used before or after surgery or for recurrent disease, with maintenance, targeted, immune or intraperitoneal approaches limited to appropriate protocols.
Related treatment guides: Chemotherapy, Targeted Therapy, Immunotherapy, Maintenance Therapy
Kidney, bladder, prostate and other genitourinary cancers use different combinations of endocrine, cytotoxic, immune and targeted treatment after disease-specific review.
Related treatment guides: Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy
Medicine selection depends on primary site, pathology, stage, previous local treatment and validated biomarkers rather than one solid-tumour package.
Related treatment guides: Chemotherapy, Immunotherapy, Targeted Therapy, Neoadjuvant Chemotherapy
Haematological cancers may require disease-specific systemic regimens, CNS-directed treatment, transplantation or selected cellular therapy under a haematology-led pathway.
Related treatment guides: Chemotherapy, Targeted Therapy, Intrathecal Chemotherapy, CAR-T Cell Therapy
therapies
The 18 current therapy records in India are grouped by clinical approach. Every link opens a separate cost guide; a service or platform name is not a treatment recommendation.
Cytotoxic, immune, targeted, endocrine and conjugated medicines use different selection tests, dosing schedules and toxicity monitoring.
Chemotherapy uses cytotoxic medicines that damage rapidly dividing cancer cells and may be given by infusion, injection or tablets in repeating treatment-and-recovery cycles.
Cancer immunotherapy uses medicines or cellular approaches intended to help the immune system recognise or attack cancer; checkpoint inhibitors are the commonest systemic example in routine solid-tumour care.
Targeted therapy uses a medicine aimed at a molecular alteration, receptor or signalling pathway that matters to a particular cancer rather than treating all cancers as biologically alike.
Hormone therapy, also called endocrine therapy, blocks hormone production or receptor signalling in cancers that depend on hormones, particularly selected breast and prostate cancers.
Molecular targeted therapy uses a medicine selected for a documented mutation, fusion, amplification or other tumour-driving alteration.
Immune checkpoint inhibitor therapy blocks signals such as PD-1, PD-L1 or CTLA-4 that can restrain immune-cell activity against cancer.
Neoadjuvant chemotherapy is systemic treatment given before a planned operation, often to shrink disease, treat microscopic spread early or show how the tumour responds.
Adjuvant chemotherapy is systemic treatment given after an operation to lower the risk from microscopic cancer cells that surgery and scans cannot show.
Palliative chemotherapy uses anticancer medicines when the stated goal is disease control, symptom relief or longer life rather than cure.
An antibody-drug conjugate links a target-seeking antibody to a cytotoxic payload, aiming to carry the drug toward cancer cells that express the relevant surface marker.
Maintenance therapy is ongoing, often lower-intensity treatment given after initial disease control to delay progression or recurrence in a protocol where maintenance has evidence.
Precision oncology connects validated pathology and molecular findings to a clinical decision; a test result alone does not establish treatment benefit.
Intraperitoneal and intrathecal delivery are indication-specific procedures with access, monitoring and complication requirements beyond an ordinary infusion.
Intraperitoneal chemotherapy delivers anticancer medicine into the abdominal cavity through a catheter or as part of an operative pathway, creating different exposure from an intravenous infusion.
Intrathecal chemotherapy delivers medicine into cerebrospinal fluid through a lumbar puncture or an implanted ventricular reservoir because ordinary bloodstream dosing may not reach the CNS adequately.
Collection, manufacturing or donor work, conditioning, inpatient monitoring and post-treatment follow-up make these complete programmes rather than single medicine administrations.
CAR-T cell therapy collects a patient's T cells, genetically engineers them to recognise a cancer target, expands them, then returns them after lymphodepleting treatment.
Bone marrow transplantation is haematopoietic stem-cell transplantation using a planned graft after conditioning; despite the familiar name, graft cells may come from marrow, peripheral blood or cord blood.
Stem cell transplantation, or haematopoietic cell transplantation, restores blood-forming cells after conditioning using the patient's own collected cells or a donor graft.
Dendritic cell therapy generally refers to an individualised vaccine approach in which antigen-presenting cells are prepared to stimulate an immune response against cancer.
Compare
These are current GAF catalog planning ranges, separated by compatible billing basis. A cycle, course, operation, test and treatment programme are not interchangeable units.
Per cycle, interval or defined regimen scope
The stored range is not comparable until medicine names, dose basis, cycle count and included monitoring are stated.
Per test-and-review episode
Confirm specimen review, assay scope, interpretation and oncology consultation rather than comparing the panel price alone.
Per named administration procedure or course
Access placement, theatre or day-care, medicine, monitoring and repeat administrations must be itemized.
Per complete named treatment programme
Eligibility, collection or donor work, manufacturing, conditioning, admission, intensive monitoring and follow-up define the scope.
| therapy | What it is used for | Typical regimen or stay | Pricing basis | GAF India planning range | Details |
|---|---|---|---|---|---|
| Chemotherapy | Chemotherapy uses cytotoxic medicines that damage rapidly dividing cancer cells and may be given by infusion, injection or tablets in repeating treatment-and-recovery cycles. | Outpatient cycles · 3–6 months typical | Per cycle, interval or defined regimen scope | $1,500–$8,000+ | View therapy |
| Immunotherapy | Cancer immunotherapy uses medicines or cellular approaches intended to help the immune system recognise or attack cancer; checkpoint inhibitors are the commonest systemic example in routine solid-tumour care. | Outpatient q2–6 weeks | Per cycle, interval or defined regimen scope | $15,000–$45,000 | View therapy |
| Targeted Therapy | Targeted therapy uses a medicine aimed at a molecular alteration, receptor or signalling pathway that matters to a particular cancer rather than treating all cancers as biologically alike. | Oral or infusion · months of therapy | Per cycle, interval or defined regimen scope | $8,000–$30,000 | View therapy |
| Hormone Therapy | Hormone therapy, also called endocrine therapy, blocks hormone production or receptor signalling in cancers that depend on hormones, particularly selected breast and prostate cancers. | Outpatient · often years of tablets | Per cycle, interval or defined regimen scope | $1,000–$4,500 | View therapy |
| Molecular Targeted Therapy | Molecular targeted therapy uses a medicine selected for a documented mutation, fusion, amplification or other tumour-driving alteration. | Oral or infusion by mutation | Per cycle, interval or defined regimen scope | $10,000–$32,000 | View therapy |
| Immune Checkpoint Inhibitor Therapy | Immune checkpoint inhibitor therapy blocks signals such as PD-1, PD-L1 or CTLA-4 that can restrain immune-cell activity against cancer. | Outpatient infusions q2–6 weeks | Per cycle, interval or defined regimen scope | $18,000–$50,000 | View therapy |
| Neoadjuvant Chemotherapy | Neoadjuvant chemotherapy is systemic treatment given before a planned operation, often to shrink disease, treat microscopic spread early or show how the tumour responds. | Cycles before surgery · 2–4 months | Per cycle, interval or defined regimen scope | $2,500–$10,000 | View therapy |
| Adjuvant Chemotherapy | Adjuvant chemotherapy is systemic treatment given after an operation to lower the risk from microscopic cancer cells that surgery and scans cannot show. | Cycles after surgery · 3–6 months | Per cycle, interval or defined regimen scope | $2,500–$10,000 | View therapy |
| Palliative Chemotherapy | Palliative chemotherapy uses anticancer medicines when the stated goal is disease control, symptom relief or longer life rather than cure. | Outpatient · goal is control, not cure | Per cycle, interval or defined regimen scope | $1,500–$7,000 | View therapy |
| Antibody-Drug Conjugate Therapy | An antibody-drug conjugate links a target-seeking antibody to a cytotoxic payload, aiming to carry the drug toward cancer cells that express the relevant surface marker. | Infusion day-care · weeks to months | Per cycle, interval or defined regimen scope | $25,000–$70,000 | View therapy |
| Maintenance Therapy | Maintenance therapy is ongoing, often lower-intensity treatment given after initial disease control to delay progression or recurrence in a protocol where maintenance has evidence. | Lower-intensity cycles after induction | Per cycle, interval or defined regimen scope | $4,000–$18,000 | View therapy |
| Precision Oncology | Precision oncology combines detailed tumour characterisation — often genomic profiling — with clinical interpretation to determine whether a molecular finding should change diagnosis, prognosis or treatment. | NGS panel + clinic visit | Per test-and-review episode | $2,000–$7,000 | View therapy |
| Intraperitoneal Chemotherapy | Intraperitoneal chemotherapy delivers anticancer medicine into the abdominal cavity through a catheter or as part of an operative pathway, creating different exposure from an intravenous infusion. | Tied to cytoreduction or IP ports | Per named administration procedure or course | $5,000–$14,000 | View therapy |
| Intrathecal Chemotherapy | Intrathecal chemotherapy delivers medicine into cerebrospinal fluid through a lumbar puncture or an implanted ventricular reservoir because ordinary bloodstream dosing may not reach the CNS adequately. | Day-care LP or Ommaya access | Per named administration procedure or course | $3,000–$10,000 | View therapy |
| CAR-T Cell Therapy | CAR-T cell therapy collects a patient's T cells, genetically engineers them to recognise a cancer target, expands them, then returns them after lymphodepleting treatment. | Apheresis + 3–6 weeks nearby | Per complete named treatment programme | $80,000–$180,000 | View therapy |
| Bone Marrow Transplantation | Bone marrow transplantation is haematopoietic stem-cell transplantation using a planned graft after conditioning; despite the familiar name, graft cells may come from marrow, peripheral blood or cord blood. | 4–8 weeks in or near the unit | Per complete named treatment programme | $25,000–$70,000 | View therapy |
| Stem Cell Transplantation | Stem cell transplantation, or haematopoietic cell transplantation, restores blood-forming cells after conditioning using the patient's own collected cells or a donor graft. | Auto or allo · 3–8 weeks | Per complete named treatment programme | $22,000–$65,000 | View therapy |
| Dendritic Cell Therapy | Dendritic cell therapy generally refers to an individualised vaccine approach in which antigen-presenting cells are prepared to stimulate an immune response against cancer. | Leukapheresis + staged infusions | Per complete named treatment programme | $8,000–$22,000 | View therapy |
Indicative planning ranges, not guaranteed hospital quotations. The treating team confirms the clinical scope, billing basis, schedule, admission, monitoring and exclusions after review.
Clinical decisions
Selection starts with a confirmed diagnosis. Histology, grade, stage, disease burden and treatment intent are reviewed alongside operative and radiation plans. A recurrence may need repeat biopsy because tumour biology and treatment sensitivity can change.
Predictive biomarkers are used only where evidence supports them for the tumour and line of therapy. Receptor results, genomic alterations and immune markers must be interpreted with sample quality, timing and previous treatment. A broad molecular panel does not guarantee an actionable medicine.
Performance status, blood counts, kidney and liver function, infection, heart or lung disease, autoimmune conditions, fertility goals, pregnancy possibility, current medicines and prior toxicity influence dose, schedule and suitability. Patient goals and the balance between likely benefit, burden and alternatives remain central.
Treatment pathway
This specialty-specific pathway is configured from approved editorial content. The exact sequence changes with the diagnosis, selected therapy and patient factors.
Pathology, imaging and clinical findings establish the cancer type, extent and treatment intent.
Indication-specific receptor, molecular or immune-marker results are checked for validity and clinical relevance.
The oncologist names the medicines, route, dose basis, schedule, expected cycles, alternatives and treatment goal.
Blood counts, organ function, infection risk, medicines, comorbidities and supportive-care needs are reviewed.
Tablets, injections, infusions or programme-specific procedures are delivered with identity, dose and safety checks.
Symptoms, examination and laboratory results guide supportive care, delay, dose modification or urgent review.
Clinical findings, imaging, markers or marrow assessment are compared with the treatment goal at appropriate intervals.
Treatment may continue, change or stop according to benefit, toxicity, patient preference and available alternatives.
Cost planning
Costs are shown by 4 compatible pricing bases rather than one misleading specialty-wide range. A personalized estimate follows medical-record review.
Medical-oncology prices are meaningful only when the billing basis is explicit. A figure may cover one cycle, a set number of cycles, a monthly medicine supply, one administration, testing plus consultation, or an entire cellular-therapy or transplant episode. These scopes must not be combined into one specialty average.
Medicine name, brand or biosimilar, dose, body-size basis, vial sharing, cycle count and pharmacy procurement can dominate a systemic-treatment estimate. Day-care, clinician fees, premedication, laboratory monitoring, scans, supportive medicines and management of complications may be billed separately.
A written estimate should identify the regimen and assumed duration, then separate predictable treatment from costs triggered by toxicity, admission, dose change or disease reassessment. Travel and accommodation between cycles are not hospital treatment charges.
Technology
This list is derived from procedure relationships; it is not a hospital machine inventory. Technology availability must be confirmed for a named campus and treatment date.
What it is
Pathology, receptor, molecular or immune-marker testing performed for a defined clinical question.
Why it may be used
It may identify or exclude an evidence-supported therapy and prevent treatment based on an unvalidated assumption.
Precision Oncology · Targeted Therapy · Molecular Targeted Therapy · Immunotherapy
What it is
A monitored setting for medicine verification, vascular access, infusion and immediate reaction management.
Why it may be used
It supports safe delivery of intravenous regimens but does not prove that every drug is stocked at every campus.
Chemotherapy · Immunotherapy · Immune Checkpoint Inhibitor Therapy · Antibody-Drug Conjugate Therapy
What it is
Procedure-specific access used to deliver medicine into cerebrospinal fluid or the abdominal cavity.
Why it may be used
Route-specific treatment requires trained teams, sterile technique and complication monitoring.
What it is
Collection, laboratory, donor, blood-bank and inpatient systems required by a named cellular or transplant programme.
Why it may be used
The complete programme and emergency capability matter more than a therapy label alone.
CAR-T Cell Therapy · Bone Marrow Transplantation · Stem Cell Transplantation · Dendritic Cell Therapy
Cities
Cities appear only where current catalog relationships contain relevant hospitals, doctors and procedures. Counts update from the live data layer.
Hospitals
29 hospitals currently meet the India and Medical Oncology relationship filters. Cards show stored CMS information, not a ranking or universal capability claim.
JCI Accredited
NABH Accredited
NABL Accredited11 listed doctors for Medical Oncology
Languages listed: English, Hindi
JCI AccreditedNABH Accredited10 listed doctors for Medical Oncology
Languages listed: English, Hindi
JCI AccreditedNABH Accredited6 listed doctors for Medical Oncology
Languages listed: English, Kannada, Hindi
JCI AccreditedNABH AccreditedNABL Accredited5 listed doctors for Medical Oncology
Languages listed: English, Hindi
JCI AccreditedNABH Accredited4 listed doctors for Medical Oncology
Languages listed: English, Telugu, Hindi
JCI AccreditedNABH AccreditedNABL Accredited4 listed doctors for Medical Oncology
Languages listed: English, Hindi
Specialists
86 doctor records meet the India and Medical Oncology relationship filters across 29 related hospitals. Profile facts come from the existing CMS; ordering is not a ranking.
Medical Oncology
18+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Medical Oncology
17+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Medical Oncology
42+ years Experience
Chemotherapy for Solid Tumors · Immunotherapy for Advanced Cancer · Immunotherapy for Solid Tumors
English, Hindi
Medical Oncology
22+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Medical Oncology
27+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Medical Oncology
22+ years Experience
MBBS— Medical Graduate · DNB (Internal Medicine)— Diplomate of Nat… · DNB (Medical Oncology) — Diplomate of Nat…
English, Hindi
Medical Oncology
14+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
International patients
Send pathology, staging images, prior treatment dates, current medicines and available biomarker reports before travel. The medical oncologist must confirm the diagnosis, treatment intent and exact regimen; a remote opinion remains provisional until clinical assessment and any required repeat testing.
Plan around treatment intervals rather than one hospital visit. Confirm where blood tests, pharmacy dispensing, infusion and emergency review occur, and whether monitoring can safely transfer to a clinician at home. Keep travel flexible through the first administration because tolerance may change the schedule.
Before departure, obtain the named regimen, doses, dates, toxicity record, response assessment and urgent-warning plan. Carry contact details for both treating and home teams and confirm medicine access if treatment continues after return.
Stay depends on the regimen and where monitoring occurs. Some infusions are day care but repeat every few weeks; tablets may still require early laboratory and toxicity review. A patient should not assume the entire planned course must occur in one country or that it can safely be split.
Cellular therapy, transplantation, severe toxicity or route-specific procedures can require admission and weeks near the treating unit. Fitness to fly depends on clinical stability, blood counts, infection risk, treatment effects and access to urgent care after return.
Depending on the condition, the treating team may request:
India has GAF-linked oncology clinicians and hospitals across several cities, but the relevant comparison is a named regimen at a named campus. Medicine procurement, biomarker testing, monitoring and emergency cover should be confirmed in writing; catalog presence is not a guarantee of stock or acceptance.
Compare like-for-like treatment intent, medicine and dose, cycle assumptions, tests, administration, supportive care and follow-up. Travel may be unsuitable when urgent treatment, frequent monitoring or continuity close to home is more important than a headline price difference.
Questions
A medical oncologist evaluates cancer, defines systemic-treatment intent, selects and monitors medicines, manages toxicity and coordinates with other cancer specialists.
No. Chemotherapy is one treatment type. Medical oncology also includes endocrine, targeted, immune and selected cellular treatments.
Selection depends on pathology, stage, biomarkers, previous treatment, organ function, expected benefit, toxicity, alternatives and the patient’s goals.
No. Testing should answer a validated question for the cancer and treatment setting; broad testing does not always change care.
There is no universal number. The regimen, intent, response and toxicity determine planned and completed cycles.
Costs must be compared by regimen and billing basis. The table keeps cycle, test, administration and programme scopes separate and does not calculate one misleading specialty average.
Only when the written estimate names them. Confirm drug, dose, cycle, administration, premedication, tests and supportive medicines.
Sometimes, if both teams agree the regimen, medicine supply, monitoring and emergency plan. A formal handover is required.
Pathology, staging images, prior treatment, biomarker reports, recent laboratory results and current clinical notes are commonly required.
The page lists hospitals with current GAF specialty relationships. Confirm the exact campus, regimen, pharmacy availability and acceptance directly.
The directory uses stored specialty and hospital relationships. Profiles are not rankings, and a named oncologist must review the case.
The treating clinician decides based on toxicity, blood counts, infection risk, hydration, thrombosis risk and access to care.
Medical information notice: This page provides general educational and travel-planning information. GAF catalog ranges are indicative planning figures, not medicine quotations, treatment recommendations or promises of acceptance or outcome. Diagnosis, treatment intent, regimen, dose, route, timing, monitoring and fitness to travel must be decided by a qualified medical oncologist and relevant multidisciplinary clinicians after reviewing the patient and complete records.
Last medically reviewed: 2026-09-14 by Dr. Saffiyyah Chaudhary. Content curated by Dr. Shabnam Choudhary.
Dr. Shabnam Choudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She contributes to the curation and development of medically informative healthcare content, helping ensure that information is structured clearly and presented in a patient-friendly manner.
Content Curator
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Dr. Saffiyyah Chaudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She provides medical review of healthcare content to help ensure that clinical information is accurate, understandable, and appropriately presented for patients and their families.
Medically Reviewed By
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Patient stories
Google reviews
5.0 from 10 reviews on the GAF Healthcare Pvt Ltd Google listing.
★★★★★
Initially I was very hesitant what to do, where to go for the treatment of my father who was suffering with prostate cancer. Thanks to google, I came into touch with Gaf Healthcare. They have arranged everything, starting from treatment plan, video consultation, airport pickup, to surgery and following up. My father was operated in Sahyadri Pune, robotic prostatectomy was done. Now he is fine.
★★★★★
The hospitality was at its point. I appreciate the great service I got from the team. Being away from Home and get the feeling like you are at home is what Gaf is doing. Thank you once more, this have lifetime memories in my life.
★★★★★
Wonderful experience with Gaf Healthcare. I was quite hesitant before traveling. But the way entire journey has been planned, charted out and facilitated by Gaf was truly exceptional. Dr. Ritu in Max has treated me well. My eye surgery went well.
★★★★★
Very nice hospitality, I have taken my mother to Fortis Hospital with help of Gaf healthcare. Initially, I was anxious but these guys made me very comfortable and mama got treated well. Thank you so much guys.
Begin
18 therapies matching your filters
